L2 Asset Management LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,049 shares of the medical research company’s stock, valued at approximately $1,942,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Korea Investment CORP purchased a new position in shares of IQVIA during the 2nd quarter worth about $13,918,000. BlackRock Inc. purchased a new stake in IQVIA in the second quarter valued at approximately $2,811,292,000. Concurrent Investment Advisors LLC increased its position in IQVIA by 36.0% during the fourth quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock worth $2,693,000 after purchasing an additional 3,161 shares during the last quarter. Focus Partners Advisor Solutions LLC purchased a new position in IQVIA during the second quarter worth approximately $976,000. Finally, Nippon Life Global Investors Americas Inc. boosted its holdings in shares of IQVIA by 36.6% in the 4th quarter. Nippon Life Global Investors Americas Inc. now owns 79,400 shares of the medical research company’s stock valued at $17,898,000 after purchasing an additional 21,270 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on IQV. William Blair raised shares of IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. BMO Capital Markets lifted their target price on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Barclays reissued an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. Mizuho upped their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.
IQVIA Price Performance
Shares of NYSE IQV opened at $260.30 on Tuesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $261.88. The company has a market capitalization of $42.85 billion, a price-to-earnings ratio of 32.30, a PEG ratio of 2.21 and a beta of 1.18. The business has a 50-day moving average of $214.97 and a 200-day moving average of $187.62.
IQVIA (NYSE:IQV – Get Free Report) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s revenue was up 8.7% on a year-over-year basis. During the same period last year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.
IQVIA declared that its board has approved a stock repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.
Insider Transactions at IQVIA
In related news, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last three months. Corporate insiders own 1.70% of the company’s stock.
IQVIA Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Read More
- Five stocks we like better than IQVIA
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
